Australia's Clarity has promising start to prostate cancer trial- Jefferies

Clarity Pharmaceuticals

30/11/2023 20:52

** Jefferies says Australia's Clarity Pharmaceuticals 
 CU6.AX  has a promising start to its clinical trial for
prostate cancer
    ** Brokerage says CU6's FY23 results were in line with its
estimates
    ** Jefferies raises price target to A$3.15 from A$2.60,
keeps rating at "buy"
    ** All the three analysts covering the stock rate it at
"buy" or higher; their median PT is A$1.70 – LSEG data
    ** Stock has risen 43.9% this year, as of last close

 (Reporting by Nausheen Thusoo in Bengaluru)
 ((Nausheen.Thusoo@thomsonreuters.com;))